Avidity Biosciences (RNA) Stock Statistics & Valuation Metrics

Avidity Biosciences has a market cap or net worth of $4.29B. The enterprise value is $3.88B.

Avidity Biosciences has 120,538,360 shares outstanding. The number of shares has decreased by -2.65% in one year.

Avidity Biosciences’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.78%.

The current PE Ratio of Avidity Biosciences is -10.07. Avidity Biosciences’s PEG ratio is 3.16.

In the last 12 months, Avidity Biosciences had revenue of 10.90M and earned -322.30M in profits. Earnings per share was -2.89.

In the last 12 months, operating cash flow was -355.32M and capital expenditures -9.90M, giving a free cash flow of -365.22M billion.

Avidity Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Avidity Biosciences upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.

Avidity Biosciences as a current ratio of 15.73, with Debt / Equity ratio of 0.45%

In the past 12 months, Avidity Biosciences has paid 0.00 in taxes.

Avidity Biosciences EV to EBITDA ratio is -8.06, with an EV/FCF ratio of -9.85.

Avidity Biosciences has $1.38B in cash and marketable securities with $5.97M in debt, giving a net cash position of -$1.37B billion.

Gross margin is 92.30%, with operating margin of -3477.43%, and net profit margin of -2957.71%.

The average price target for Avidity Biosciences is $64.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy